PDCD1 and intrahepatic cholangiocarcinoma: Consistent with our results, the median PFS of lenvatinib plus PD-1/PD-L1 inhibitors from a recent study was 8.63 months in ICC patients, longer than lenvatinib alone though slightly shorter than the results of our study (25).